WebNov 7, 2024 · Uses for Atacand HCT. Candesartan and hydrochlorothiazide combination is used to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. ... Hyperkalemia (high potassium in the blood) may occur while you are using this medicine. Check with your doctor right away if you have stomach pain ... WebJan 31, 2024 · Atacand HCT side effects. Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or …
Atacand HCT Side Effects: Common, Severe, Long Term - Drugs.com
WebDec 13, 2024 · ATACAND has been evaluated for safety in more than 3600 patients/subjects, including more than 3200 patients treated for hypertension. About 600 of these patients were studied for at least 6 … WebMay 7, 2024 · ATACAND HCT 32-25 contains 32 mg of candesartan cilexetil and 25 mg of hydrochlorothiazide. The inactive ingredients of the tablets are carboxymethylcellulose calcium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, cornstarch, polyethylene glycol 8000, and ferric oxide (yellow). Ferric oxide (reddish brown) is also … the norumbega foundation
Angiotensin II receptor blockers - Mayo Clinic
WebATACAND is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension in adults and children 1 to < 17 years of age ... Hyperkalemia may occur in heart failure patients treated with ATACAND (5.6). Most common adverse reactions which caused adult patients to WebSide effects of Atacand and Benicar that are similar include dizziness, back pain, joint pain, stomach pain, diarrhea, or headache. Side effects of Atacand that are different from Benicar include runny or stuffy nose, sore throat, cough, tired feeling, feeling like you might pass out, chest pain, swelling in your hands or feet, slow heart rate ... WebThe incidence of hyperkalemia leading to drug discontinuation in ATACAND-treated patients was 2.4% compared with 0.6% in placebo-treated patients. In the CHARM-Added program where candesartan or placebo was given in addition to ACE inhibitors, the incidence of hyperkalemia was 9.5% in patients treated with ATACAND versus 3.5% in … the nor\\u0027easter